Tumor Registry of Lymphatic Neoplasia

Study Overview
=================
Brief Summary
-----------------
The purpose of this registry is to record information on therapy reality of malignant lymphatic systemic diseases by office-based haematologists in Germany.

Detailed Description
-----------------
The TLN is a prospective, longitudinal, nation wide cohort study with the purpose to record information on the antineoplastic treatment of lymphatic neoplasms in Germany. The registry will follow patients for up to five years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. The impact of nutrition (LyNut) and physical activity (LyNut) on the course of the adjuvant disease will be examined in patients with indolent and aggressive Non-Hodgin Lymphoma, as well as long-term effects of systemic treatment (LyTox) and quality of life (LyLife) in patients with multiple myeloma.

Official Title
-----------------
Epidemiological Registry Describing Treatment Reality and Therapy Modalities of Patients With Malignant Lymphatic Systemic Diseases (Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma) Requiring Therapy.

Conditions
-----------------
Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM)

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Confirmed diagnosis of Non-Hodgkin's lymphoma, chronic lymphocytic leukaemia or multiple myeloma Must receive a first- or second-line therapy 18 years or older Signed, written informed consent Exclusion Criteria: - no systemic therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Course of treatment (treatment reality) | Documentation of anamnestic data and therapy sequences | 5 years per patient | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effectiveness of treatment | Documentation of response rates and progression-free survival per therapy sequence, overall survival time and adverse reactions | 5 years per patient | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Malignant lymphatic disease, therapy-reality, observation, registry, therapy sequences, NHL, CLL, Germany, lenalidomide, alemtuzumab, rituximab, bendamustin, thalidomide, bortezomib, ibritumomab-tiuxetan, G-CSF (Granulocyte-Colony Stimulating Factor), chronic lymphocytic leukaemia, follicular lymphoma, gastric MALT lymphoma (Mucosa Associated Lymphoid Tissue), nongastric MALT lymphoma (Mucosa Associated Lymphoid Tissue), nodal marginal zone lymphoma, splenic marginal zone lymphoma, mantle cell lymphoma, diffuse large b-cell lymphoma